JFL Life Sciences
JFL Life Sciences Share Price Chart
JFL Life Sciences last traded at ₹10.25 (2026-10-13). Over the past month the stock moved -3.8%, three months the stock moved +13.3%, year the stock moved -15.8%. Its closing range over 52 weeks is ₹8.55 – ₹13.20, with the latest close 22.3% below the high.
Closing prices up to 2026-10-13.
About JFL Life Sciences
Incorporated in 2010, JFL Life Sciences Ltd produces and markets a wide range of formulations[1]
Business Overview:[1] JFLLSL is a WHO-GMP Certified pharmaceutical company that manufactures and sells products across multiple markets. It specializes in Dry Powder Injectable Solid Oral Dosage Forms (Beta-Lactam & General)
Fundamentals
Quarterly Results
In the latest quarter (Jun 2026), JFL Life Sciences reported sales of ₹11.10 crore (-4.2%) and net profit of ₹1.11 crore (+48.0%), compared with the same quarter last year.
| Period | Sales | Operating profit | OPM % | Net profit | EPS (₹) |
|---|---|---|---|---|---|
| Jun 2026 | 11.10 | 2.09 | 18.83 | 1.11 | 0.17 |
| Mar 2026 | 63.05 | 3.51 | 5.57 | 1.66 | 0.25 |
| Dec 2025 | 26.84 | 3.35 | 12.48 | 2.02 | 0.31 |
| Sep 2025 | 29.91 | 2.91 | 9.73 | 1.97 | 0.30 |
| Jun 2025 | 11.59 | 1.93 | 16.65 | 0.75 | 0.11 |
| Mar 2025 | 11.73 | 1.38 | 11.76 | 0.08 | 0.01 |
| Dec 2024 | 21.25 | 1.35 | 6.35 | 0.74 | 0.11 |
| Sep 2024 | 39.51 | 2.41 | 6.10 | 1.45 | 0.22 |
| Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 | |
|---|---|---|---|---|---|---|
| Sales growth | -45.9% | +21.5% | -24.3% | +26.3% | +437.5% | -4.2% |
| Operating profit growth | -11.0% | -36.9% | +20.7% | +148.1% | +154.3% | +8.3% |
| Net profit growth | -93.3% | -60.7% | +35.9% | +173.0% | +1975.0% | +48.0% |
| EPS growth | -94.4% | -62.1% | +36.4% | +181.8% | +2400.0% | +54.5% |
| OPM % | 11.8% | 16.7% | 9.7% | 12.5% | 5.6% | 18.8% |
Colour scale: below -5% -5% to 0% 0% to 5% 5% to 20% 20% and above. A dash means the earlier figure was zero or negative, so a percentage is not meaningful.
Annual Financials
In the latest year (Mar 2026), JFL Life Sciences reported sales of ₹131.00 crore (+59.7%) and net profit of ₹6.00 crore (+44.2%), compared with the previous year.
| Period | Sales | Operating profit | OPM % | Net profit | EPS (₹) |
|---|---|---|---|---|---|
| Mar 2026 | 131.00 | 12.00 | 9.00 | 6.00 | 0.97 |
| Mar 2025 | 82.04 | 8.20 | 10.00 | 4.16 | 1.26 |
| Mar 2024 | 46.55 | 4.55 | 9.77 | 3.31 | 1.00 |
| Mar 2023 | 42.83 | 3.92 | 9.15 | 2.81 | 0.85 |
| Mar 2022 | 33.59 | 5.36 | 15.96 | 2.81 | 1.17 |
| Mar 2021 | 32.77 | 2.16 | 6.59 | 0.54 | 2.84 |
| Mar 2020 | 30.17 | 1.86 | 6.17 | 0.36 | 2.77 |
| Mar 2019 | 31.78 | 1.33 | 4.19 | 0.30 | 2.31 |
| Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|---|
| Sales growth | -5.1% | +8.6% | +2.5% | +27.5% | +8.7% | +76.2% | +59.7% |
| Operating profit growth | +39.8% | +16.1% | +148.1% | -26.9% | +16.1% | +80.2% | +46.3% |
| Net profit growth | +20.0% | +50.0% | +420.4% | +0.0% | +17.8% | +25.7% | +44.2% |
| EPS growth | +19.9% | +2.5% | -58.8% | -27.4% | +17.6% | +26.0% | -23.0% |
| OPM % | 6.2% | 6.6% | 16.0% | 9.2% | 9.8% | 10.0% | 9.0% |
Colour scale: below -5% -5% to 0% 0% to 5% 5% to 20% 20% and above. A dash means the earlier figure was zero or negative, so a percentage is not meaningful.
Shareholding
AI Analysis
No AI analysis generated yet for JFL Life Sciences.
Get Free AI Stock Analysis FREE →Latest News
-
RPG Life Sciences completes slump sale of APIs business to Raghava - scanx.trade
-
RPG Life Sciences rises on deal to acquire API business of Raghava Life Sciences - Business Standard
-
Aragen Life Sciences Files Draft Papers With Sebi; Eyes Rs 800-Cr via Fresh Issue
-
Aragen Life Sciences files draft papers with Sebi to raise funds through IPO - The Economic Times
-
Aragen Life Sciences files draft papers with SEBI; eyes ₹800-cr via fresh issue - BusinessLine
-
Alivus Life Sciences acquires 76% stake in IQGenX Pharma for ₹9.12 crore - scanx.trade
-
Alivus Life Sciences acquires 76% stake in IQGenX Pharma - Business Standard
-
Alivus Life Sciences acquires 76% stake in IQGenX Pharma for ₹9.12 crore - scanx.trade
-
Alivus Life Sciences acquires 76% stake in IQGenX Pharma - Business Standard
-
Sai Life Sciences Ltd up for third consecutive session - business-standard.com
Frequently Asked Questions
What is JFL Life Sciences's current stock price?
JFL Life Sciences shares were last quoted at ₹10.25 (+0.0% on the day). Use the Refresh price button on this page for the latest available price. Prices are for information only.
What is the P/E ratio of JFL Life Sciences?
JFL Life Sciences has a price-to-earnings (P/E) ratio of 10.05 and a price-to-book (P/B) ratio of 0.85. The industry P/E is 53.33.
What is the 52-week high and low of JFL Life Sciences?
The 52-week high of JFL Life Sciences is ₹15.40 and the 52-week low is ₹8.55.
What is the market cap of JFL Life Sciences?
The market capitalisation of JFL Life Sciences is about ₹68.30 crore.
How did JFL Life Sciences perform in its latest quarterly results?
In the latest quarter (Jun 2026), JFL Life Sciences reported sales of ₹11.10 crore (-4.2%) and net profit of ₹1.11 crore (+48.0%), compared with the same quarter last year.
Is JFL Life Sciences a good stock to buy?
This page is for information and is not investment advice. As per the data shown here, JFL Life Sciences has a 3-year ROE of 12.00%, 3-year profit growth of 32.00%. Review the fundamentals, quarterly results and AI analysis on StockSpin, and consult a SEBI-registered adviser before investing.
What is the promoter holding in JFL Life Sciences?
Promoters hold about 67.47% of JFL Life Sciences.
Which sector does JFL Life Sciences belong to?
JFL Life Sciences belongs to the Pharmaceuticals & Drugs sector.